Evidence map›Paper›PMID 41959816›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Development and validation of a machine learning model for community-based tuberculosis screening among persons aged ≥ 15 years in South Africa and Zambia.

Alexandra J Zimmer, Kindie Fentahun Muchie, Henry Loharja, Lisa Koeppel, Helen Ayles, Maria Del Mar Castro, Evangelia Christodoulou, Greg J Fox, Mary Gaeddert, Yohhei Hamada and 18 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Alexandra J ZimmerHeidelberg University Medical Faculty, Heidelberg University Hospital, Department of Infectious Disease and Tropical Medicine, Heidelberg, Germany.ORCID 0000-0002-6047-0923
Kindie Fentahun MuchieHeidelberg University Medical Faculty, Heidelberg University Hospital, Department of Infectious Disease and Tropical Medicine, Heidelberg, Germany.
Henry LoharjaHeidelberg University Medical Faculty, Heidelberg University Hospital, Department of Infectious Disease and Tropical Medicine, Heidelberg, Germany.
Lisa KoeppelHeidelberg University Medical Faculty, Heidelberg University Hospital, Department of Infectious Disease and Tropical Medicine, Heidelberg, Germany.
Helen AylesZambart, University of Zambia School of Public Health Ridgeway Campus, Lusaka, Zambia.
Maria Del Mar CastroHeidelberg University Medical Faculty, Heidelberg University Hospital, Department of Infectious Disease and Tropical Medicine, Heidelberg, Germany.ORCID 0000-0002-0485-2919
Evangelia ChristodoulouGerman Cancer Research Center (DKFZ) Heidelberg, Div. Intelligent Medical Systems, Germany.
Greg J FoxFaculty of Medicine and Health, The University of Sydney, Sydney, NSW Australia 2006.
Mary GaeddertHeidelberg University Medical Faculty, Heidelberg University Hospital, Department of Infectious Disease and Tropical Medicine, Heidelberg, Germany.ORCID 0000-0002-6713-3495
Yohhei HamadaInstitute for Global Health, University College London, London, United Kingdom.
Chris IsaacsConnected Diagnostics Ltd, London.
Nathan KapataMedical Faculty, Heidelberg University, Germany.
Pascalina Chanda-KapataIndependent Health and Development Consultant, Lusaka, Zambia.
Kasra KarimiHeidelberg University Medical Faculty, Heidelberg University Hospital, Department of Infectious Disease and Tropical Medicine, Heidelberg, Germany.
Nkatya KaseseZambart, University of Zambia School of Public Health Ridgeway Campus, Lusaka, Zambia.
Andrew D KerkhoffDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-5023-6658
Irwin LawDepartment for HIV, tuberculosis, hepatitis and sexually transmitted infections, World Health Organization, Geneva, Switzerland.
Lena Maier-HeinGerman Cancer Research Center (DKFZ) Heidelberg, Div. Intelligent Medical Systems, Germany.
Florian M MarxHeidelberg University Medical Faculty, Heidelberg University Hospital, Department of Infectious Disease and Tropical Medicine, Heidelberg, Germany.
Minyoi M MaimbolwaTuberculosis Department, Centre of Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Sizulu MoyoHuman Sciences Research Council, Cape Town, South Africa; Faculty of Medical and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Thuli MthiyaneSouth Africa Medical Research Council, Pretoria, South Africa.
Monde MuyoyetaTuberculosis Department, Centre of Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Joacim RocklövHuman Sciences Research Council, Cape Town, South Africa; Faculty of Medical and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Ab SchaapZambart, University of Zambia School of Public Health Ridgeway Campus, Lusaka, Zambia.
Seda YerlikayaHeidelberg University Medical Faculty, Heidelberg University Hospital, Department of Infectious Disease and Tropical Medicine, Heidelberg, Germany.
Michael OpataInterdisciplinary Centre for Scientific Computing, Heidelberg University, Heidelberg, Germany.
Claudia M DenkingerHeidelberg University Medical Faculty, Heidelberg University Hospital, Department of Infectious Disease and Tropical Medicine, Heidelberg, Germany.

Funding

Rapid Research for Diagnostics Development in TB Network (R2D2 TB Network)U01AI152087 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CATTAMANCHI, ADITHYA, DENKINGER, CLAUDIA MARIA · 2020 to 2024
$19.3M
Rapid Research for Diagnostics Development in TB Network: Episode 2 (R2D2 TB Network II)R01AI190419 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adithya Cattamanchi, Claudia Maria Denkinger · 2025 to 2026
$10.1M
NIAID NIH HHS R01 AI190419NIAID NIH HHS U01 AI152087
6 · The paper itself

Abstract

Introduction: Current tuberculosis (TB) screening tools, such as the WHO four-symptom screen (W4SS), lack sufficient sensitivity and specificity for effective community-based active case finding, contributing to both missed diagnoses and unnecessary diagnostic evaluations. This study aimed to develop and validate a machine learning (ML) model to improve TB risk prediction among persons aged ≥15 years in community settings of Zambia and South Africa. Methods: A large, harmonized dataset was created from four community-based TB prevalence surveys in South Africa and Zambia (N=169,813), restricted to individuals not under treatment at the time of survey. A binary reference outcome was defined based on available microbiological and radiographic data, grouping individuals as either 'Possible TB' or 'Unlikely TB'. An XGBoost model was trained on 80% (N=135,854) of the data using demographic, clinical, and socio-economic variables, and model interpretability was assessed using SHapley Additive exPlanations (SHAP) values. Internal validation was performed using a 20% hold-out test set (N=33,959). Model performance was assessed using discrimination, calibration, and clinical utility measures compared to the W4SS and against WHO's 2025 Target Product Profile (TPP) for a tool in a two-step screening algorithm. Results: Overall, 16,413 (9.7%) of individuals were labelled as 'Possible TB'. On the test set, the XGBoost model yielded an area under the curve (AUC) of 79.7% (95% CI: 78.7, 80.7), outperforming the W4SS (AUC 57.0%; 95% CI: 56.1, 57.8). The XGBoost model achieved 81.5% sensitivity (95% CI: 77.6, 84.9) at a 60% specificity threshold. This exceeded the W4SS, which achieved only 38.2% sensitivity (95% CI: 36.5, 39.9) on the same dataset. SHAP analysis identified age, previous TB treatment, times treated for TB and unemployment as the primary contributors to risk. Conclusion: The ML XGBoost model shows promise as a screening tool to support community-based active case finding activities prior to diagnostic testing. However, as performance remained below TPP targets, and adding variables, e.g. on geolocation, could be considered. Registration: The study was not registered.

Identifiers

PMID41959816
PMCPMC13060419

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.